Tydén Gunnar, Kumlien Gunilla, Genberg Helena, Sandberg John, Sedigh Amir, Lundgren Torbjörn, Gjertsen Henrik, Fehrman Ingela
Department of Transplantation Surgery, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
Xenotransplantation. 2006 Mar;13(2):105-7. doi: 10.1111/j.1399-3089.2006.00292.x.
ABO-incompatible kidney transplantations have previously only been performed after several pre-operative sessions of plasmapheresis followed by splenectomy, and with the conventional triple-drug immunosuppressive protocol being reinforced with anti-lymphocyte globulin and B-cell-specific drugs. We have designed a protocol without splenectomy, based on antigen-specific immunoadsorption, rituximab and a conventional triple-drug immunosuppressive protocol.
The protocol called for a 1-month pre-transplantation conditioning period, starting with one dosage of rituximab and followed by full-dose tacrolimus, mycophenolate mofetil and prednisolone. Antigen-specific immunoadsorption was performed on pre-transplantation days -6, -5, -2 and -1. After the last session, 0.5 g/kg of intravenous immunoglobulin (IVIG) was administered. Postoperatively, three more apheresis sessions were given every third day.
Twenty-one patients have received transplants with this protocol. The ABO-antibodies (Abs) were readily removed by the antigen-specific immunoadsorption and were kept at a low level post-transplantation by further adsorptions. There were no side effects, and all but one patient have normal renal transplant function.
We conclude that after one infusion each of rituximab and IVIG, and antigen-specific immunoadsorption, blood-group incompatible renal transplantations can be performed with standard immunosuppression and without splenectomy, and with excellent short- and long-term results.
此前,ABO血型不相容的肾移植仅在术前进行多次血浆置换并随后行脾切除术后进行,且传统的三联药物免疫抑制方案需用抗淋巴细胞球蛋白和B细胞特异性药物强化。我们设计了一种无需脾切除的方案,该方案基于抗原特异性免疫吸附、利妥昔单抗和传统的三联药物免疫抑制方案。
该方案要求在移植前有1个月的预处理期,开始时给予一剂利妥昔单抗,随后给予全剂量的他克莫司、霉酚酸酯和泼尼松龙。在移植前第-6、-5、-2和-1天进行抗原特异性免疫吸附。在最后一次治疗后,给予0.5 g/kg的静脉注射免疫球蛋白(IVIG)。术后,每三天再进行三次血液分离治疗。
21例患者采用该方案接受了移植。ABO抗体通过抗原特异性免疫吸附很容易被清除,并且通过进一步吸附在移植后保持在低水平。没有副作用,除1例患者外,所有患者的肾移植功能均正常。
我们得出结论,在分别输注一次利妥昔单抗和IVIG以及进行抗原特异性免疫吸附后,血型不相容的肾移植可以在标准免疫抑制下进行,无需脾切除,且短期和长期效果良好。